News J&J's Tremfya gets funding in Germany and UK Johnson & Johnson’s psoriasis drug Tremfya has been given the green light for funding by cost-effectiveness bodies in the UK and Germany.
Views & Analysis Who should pay for HTA? Part of the drive for strengthening EU cooperation on health technology assessment (HTA) is to tackle duplication of work
News Lung cancer drug Keytruda to become routinely available on N... NICE has given the green light for lung cancer drug Keytruda to be used as a routine treatment for certain patients in England.
News Pfizer will have to cut price of AML drug Mylotarg after NIC... NICE blocks access to 65% of patients on cost grounds
News NICE asks EUSA pharma to drop price of neuroblastoma drug NICE calls for price cut before possible CDF funding
News Report warns of UK's rare disease 'postcode lottery' There is still a ‘postcode lottery’ for patients getting access to vital rare disease treatments in the UK, according to a new report.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
